Les traitements sont-ils personnalisés selon la charge tumorale ?
Oui, les traitements sont souvent adaptés en fonction de la charge tumorale et du type de cancer.
Traitements personnalisésCharge tumoraleType de cancer
Complications
5
#1
Quelles complications peuvent survenir avec une charge tumorale élevée ?
Complications incluent métastases, douleurs chroniques et défaillance organique.
ComplicationsMétastasesDéfaillance organique
#2
La charge tumorale affecte-t-elle le pronostic ?
Oui, une charge tumorale élevée est souvent associée à un pronostic moins favorable.
PronosticCharge tumoraleÉvaluation du risque
#3
Comment la charge tumorale influence-t-elle la qualité de vie ?
Elle peut réduire la qualité de vie en provoquant douleur, fatigue et limitations fonctionnelles.
Qualité de vieFatigueLimitations fonctionnelles
#4
Les complications sont-elles réversibles ?
Certaines complications peuvent être traitées, mais d'autres peuvent être permanentes.
ComplicationsTraitementRéversibilité
#5
La gestion de la douleur est-elle importante ?
Oui, la gestion de la douleur est cruciale pour améliorer la qualité de vie des patients.
Gestion de la douleurQualité de viePatients
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque de cancer ?
Les principaux facteurs incluent le tabagisme, l'alcool, l'obésité et l'exposition à des produits chimiques.
Facteurs de risqueTabagismeObésité
#2
L'hérédité joue-t-elle un rôle dans la charge tumorale ?
Oui, des antécédents familiaux de cancer peuvent augmenter le risque de charge tumorale.
HéréditéAntécédents familiauxCharge tumorale
#3
L'âge est-il un facteur de risque ?
Oui, le risque de développer une charge tumorale augmente avec l'âge.
ÂgeFacteurs de risqueCharge tumorale
#4
Les infections peuvent-elles influencer la charge tumorale ?
Certaines infections, comme le HPV ou l'hépatite B, peuvent augmenter le risque de cancer.
InfectionsHPVHépatite B
#5
Le mode de vie influence-t-il la charge tumorale ?
Oui, un mode de vie sain peut réduire le risque de cancer et la charge tumorale associée.
Mode de vieRisque de cancerCharge tumorale
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Charge tumorale : Questions médicales les plus fréquentes",
"headline": "Charge tumorale : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Charge tumorale : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-13",
"dateModified": "2026-04-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Charge tumorale"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Techniques d'investigation",
"url": "https://questionsmedicales.fr/mesh/D008919",
"about": {
"@type": "MedicalCondition",
"name": "Techniques d'investigation",
"code": {
"@type": "MedicalCode",
"code": "D008919",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E05"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Charge tumorale",
"alternateName": "Tumor Burden",
"code": {
"@type": "MedicalCode",
"code": "D047368",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Razelle Kurzrock",
"url": "https://questionsmedicales.fr/author/Razelle%20Kurzrock",
"affiliation": {
"@type": "Organization",
"name": "MCW Cancer Center and Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, WIS, USA."
}
},
{
"@type": "Person",
"name": "Sara M Tolaney",
"url": "https://questionsmedicales.fr/author/Sara%20M%20Tolaney",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. sara_tolaney@dfci.harvard.edu eliezerm_vanallen@dfci.harvard.edu."
}
},
{
"@type": "Person",
"name": "Albrecht Stenzinger",
"url": "https://questionsmedicales.fr/author/Albrecht%20Stenzinger",
"affiliation": {
"@type": "Organization",
"name": "Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany."
}
},
{
"@type": "Person",
"name": "Xiao-Dong Jiao",
"url": "https://questionsmedicales.fr/author/Xiao-Dong%20Jiao",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200433, China."
}
},
{
"@type": "Person",
"name": "Bao-Dong Qin",
"url": "https://questionsmedicales.fr/author/Bao-Dong%20Qin",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200433, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis.",
"datePublished": "2024-03-01",
"url": "https://questionsmedicales.fr/article/38181123",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/JS9.0000000000001022"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effective dose window for containing tumor burden under tolerable level.",
"datePublished": "2023-05-23",
"url": "https://questionsmedicales.fr/article/37221258",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41540-023-00279-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cutaneous Neurofibroma Heterogeneity: Factors that Influence Tumor Burden in Neurofibromatosis Type 1.",
"datePublished": "2023-06-15",
"url": "https://questionsmedicales.fr/article/37318402",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jid.2022.12.027"
}
},
{
"@type": "ScholarlyArticle",
"name": "Peripheral surrogates of tumor burden to guide chemotherapeutic and immunotherapeutic strategies for HPV-associated malignancies.",
"datePublished": "2023-08-10",
"url": "https://questionsmedicales.fr/article/38958745",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.18632/oncotarget.28487"
}
},
{
"@type": "ScholarlyArticle",
"name": "High tumor burden score indicated the unfavorable prognosis in patients with hepatocellular carcinoma: A meta-analysis.",
"datePublished": "2024-08-08",
"url": "https://questionsmedicales.fr/article/39116157",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0308570"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Techniques d'investigation",
"item": "https://questionsmedicales.fr/mesh/D008919"
},
{
"@type": "ListItem",
"position": 3,
"name": "Charge tumorale",
"item": "https://questionsmedicales.fr/mesh/D047368"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Charge tumorale - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Charge tumorale",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Charge tumorale",
"description": "Comment évaluer la charge tumorale ?\nQuels tests sont utilisés pour mesurer la charge tumorale ?\nLa charge tumorale peut-elle être quantifiée ?\nQuel rôle joue l'imagerie dans le diagnostic ?\nLes marqueurs tumoraux sont-ils fiables ?",
"url": "https://questionsmedicales.fr/mesh/D047368#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Charge tumorale",
"description": "Quels symptômes indiquent une charge tumorale élevée ?\nLa charge tumorale affecte-t-elle la douleur ?\nPeut-on avoir des symptômes sans charge tumorale ?\nComment la charge tumorale influence-t-elle la fatigue ?\nLes symptômes varient-ils selon le type de cancer ?",
"url": "https://questionsmedicales.fr/mesh/D047368#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Charge tumorale",
"description": "Peut-on prévenir la charge tumorale ?\nQuels facteurs de risque augmentent la charge tumorale ?\nLa vaccination peut-elle réduire la charge tumorale ?\nComment le dépistage aide-t-il à prévenir la charge tumorale ?\nL'alimentation influence-t-elle la charge tumorale ?",
"url": "https://questionsmedicales.fr/mesh/D047368#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Charge tumorale",
"description": "Quels traitements ciblent la charge tumorale ?\nLa chirurgie réduit-elle la charge tumorale ?\nComment la radiothérapie affecte-t-elle la charge tumorale ?\nL'immunothérapie est-elle efficace contre la charge tumorale ?\nLes traitements sont-ils personnalisés selon la charge tumorale ?",
"url": "https://questionsmedicales.fr/mesh/D047368#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Charge tumorale",
"description": "Quelles complications peuvent survenir avec une charge tumorale élevée ?\nLa charge tumorale affecte-t-elle le pronostic ?\nComment la charge tumorale influence-t-elle la qualité de vie ?\nLes complications sont-elles réversibles ?\nLa gestion de la douleur est-elle importante ?",
"url": "https://questionsmedicales.fr/mesh/D047368#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Charge tumorale",
"description": "Quels sont les principaux facteurs de risque de cancer ?\nL'hérédité joue-t-elle un rôle dans la charge tumorale ?\nL'âge est-il un facteur de risque ?\nLes infections peuvent-elles influencer la charge tumorale ?\nLe mode de vie influence-t-il la charge tumorale ?",
"url": "https://questionsmedicales.fr/mesh/D047368#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer la charge tumorale ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La charge tumorale est évaluée par imagerie, biopsie et marqueurs tumoraux."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour mesurer la charge tumorale ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'IRM, le scanner et les analyses sanguines pour les marqueurs."
}
},
{
"@type": "Question",
"name": "La charge tumorale peut-elle être quantifiée ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être quantifiée par des indices comme le nombre de lésions ou leur taille."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'imagerie dans le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie aide à localiser et à mesurer la taille des tumeurs, évaluant la charge."
}
},
{
"@type": "Question",
"name": "Les marqueurs tumoraux sont-ils fiables ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent indiquer la charge tumorale, mais ne sont pas toujours spécifiques."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une charge tumorale élevée ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Symptômes incluent fatigue, douleur, perte de poids et anomalies fonctionnelles."
}
},
{
"@type": "Question",
"name": "La charge tumorale affecte-t-elle la douleur ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une charge tumorale élevée peut entraîner des douleurs dues à la pression sur les organes."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans charge tumorale ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains symptômes peuvent être causés par d'autres conditions non tumorales."
}
},
{
"@type": "Question",
"name": "Comment la charge tumorale influence-t-elle la fatigue ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une charge tumorale élevée peut provoquer une fatigue due à l'inflammation et au métabolisme tumoral."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de cancer ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes dépendent du type de cancer et de la localisation des tumeurs."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la charge tumorale ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un mode de vie sain, dépistage et vaccination contre certains cancers."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque augmentent la charge tumorale ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le tabagisme, l'obésité, l'exposition à des agents cancérigènes."
}
},
{
"@type": "Question",
"name": "La vaccination peut-elle réduire la charge tumorale ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines vaccins, comme ceux contre le HPV, peuvent prévenir des cancers."
}
},
{
"@type": "Question",
"name": "Comment le dépistage aide-t-il à prévenir la charge tumorale ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le dépistage précoce permet de détecter des cancers à un stade précoce, réduisant la charge."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle la charge tumorale ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée peut réduire le risque de certains cancers et leur charge."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent la charge tumorale ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chimiothérapie, la radiothérapie et l'immunothérapie."
}
},
{
"@type": "Question",
"name": "La chirurgie réduit-elle la charge tumorale ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la chirurgie peut enlever des tumeurs, réduisant ainsi la charge tumorale."
}
},
{
"@type": "Question",
"name": "Comment la radiothérapie affecte-t-elle la charge tumorale ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La radiothérapie cible et détruit les cellules tumorales, diminuant la charge."
}
},
{
"@type": "Question",
"name": "L'immunothérapie est-elle efficace contre la charge tumorale ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle stimule le système immunitaire pour attaquer les cellules tumorales."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés selon la charge tumorale ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent adaptés en fonction de la charge tumorale et du type de cancer."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une charge tumorale élevée ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Complications incluent métastases, douleurs chroniques et défaillance organique."
}
},
{
"@type": "Question",
"name": "La charge tumorale affecte-t-elle le pronostic ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une charge tumorale élevée est souvent associée à un pronostic moins favorable."
}
},
{
"@type": "Question",
"name": "Comment la charge tumorale influence-t-elle la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut réduire la qualité de vie en provoquant douleur, fatigue et limitations fonctionnelles."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être traitées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "La gestion de la douleur est-elle importante ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la gestion de la douleur est cruciale pour améliorer la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque de cancer ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent le tabagisme, l'alcool, l'obésité et l'exposition à des produits chimiques."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans la charge tumorale ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer peuvent augmenter le risque de charge tumorale."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de développer une charge tumorale augmente avec l'âge."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles influencer la charge tumorale ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections, comme le HPV ou l'hépatite B, peuvent augmenter le risque de cancer."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il la charge tumorale ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain peut réduire le risque de cancer et la charge tumorale associée."
}
}
]
}
]
}
Gastrointestinal Cancer Center, Linz, Austria; Department of Surgery, Ordensklinikum Linz, Austria; Johannes Kepler University Linz, Medical Faculty, Linz, Austria.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2021-12-01
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2021-12-01
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2021-12-01
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2021-12-01
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
2021-12-01
Various immunotherapy has been greatly applied to comprehensive treatment of malignant cancer under different degrees of tumor burden. Scientific researchers have gained considerable progress in the r...
A maximum-tolerated dose (MTD) reduces the drug-sensitive cell population, though it may result in the competitive release of drug resistance. Alternative treatment strategies such as adaptive therapy...
Neurofibromatosis type 1 is one of the most common genetic disorders of the nervous system and predisposes patients to develop benign and malignant tumors. Cutaneous neurofibromas (cNFs) are NF1-assoc...
With the rapid adoption of immunotherapy into clinical practice for HPV-associated malignancies, assessing tumor burden using "liquid biopsies" would further our understanding of clinical outcomes med...
Tumor burden score (TBS) based on maximum tumor diameter and number has been shown to correlate with prognosis in patients with hepatocellular carcinoma (HCC). Nevertheless, the results are conflictin...
A comprehensively search of the databases including PubMed, Embase and Web of Science was performed to retrieve studies satisfying the inclusion criteria until August 31, 2023. The hazard ratios (HRs)...
10 retrospective studies containing 25073 patients were incorporated in the study. The results demonstrated that high TBS was markedly association with poor overall survival (OS) (HR: 1.79, 95% CI: 1....
TBS may be an efficient prognostic index in HCC patients....
The biomarkers of immune checkpoint inhibitors in the treatment of non-small cell lung cancer (NSCLC) patients have limited predictive performance. In this study we aimed to investigate the feasibilit...
From February 2017 to November 2020, pretreatment and on-treatment (3~6 weeks after first cycle of immunotherapy) dynamic plasma ctDNA samples from NSCLC patients receiving immune monotherapy or combi...
We found that patients without detectable baseline ctDNA had better survival outcomes (median overall survival [OS]: not reached vs. 12.8 months; hazard ratio [HR], 0.15; p = 0.035]). RB1 and SMARCA4 ...
ΔmTBI had a good sensitivity to identify potential beneficial patients based on the best effect CT scans, demonstrating that mTBI dynamics were predictive of benefit from immune checkpoint blockade....
The pathological tumor burden score (TBS) has been proven to be a better risk stratification tool for liver metastasis of colorectal cancer than the traditional clinical risk score (CRS). The aim of t...
A total of 348 patients with colorectal liver metastases (CRLM) who underwent curative hepatic resection were retrospectively enrolled from September 1999 to December 2016. Univariable and multivariab...
Patients who received NAC had a higher median TBS than patients who did not receive NAC (4.07 vs. 2.69, P < 0.001). Among patients who did not receive NAC, those with TBS > 3 showed a significantly wo...
Pathological TBS can be applied to predict the RFS and OS of patients suffering from CRLM who did not receive NAC. However, pathological TBS might not be regard as prognosis in patients who did receiv...
A preoperative predictive score for hepatocellular carcinoma (HCC) can help stratify patients who undergo resection relative to long-term outcomes and tailor treatment strategies....
Patients who underwent curative-intent hepatectomy for HCC between 2000 and 2020 were identified from an international multi-institutional database. A risk score (mFIBA) was developed using an Eastern...
Among 957 patients, 443 and 514 patients were included from the Eastern and Western cohorts, respectively. On multivariable analysis, alpha-feto protein (HR1.97, 95%CI 1.42-2.72), neutrophil-to-lympho...
The online mFIBA calculator may help surgeons with clinical decision-making to individualize perioperative treatment strategies for patients undergoing resection of HCC....
The purpose of our study was to explore and compare the tumor burden of different bone marrow infiltration patterns and evaluate the feasibility of apparent diffusion coefficient (ADC) value to identi...
Ninety-three patients with newly diagnosed multiple myeloma and 23 controls had undergone routine magnetic resonance imaging (MRI) and diffusion-weighted MRI (DWI) from January 2019 to November 2020. ...
The values of hemoglobin, beta-2 microglobulin (β2-MG), plasma cell, M protein, the percentages of stage, high-risk fluorescence in situ hybridization, and ADC values showed significant difference amo...
The bone marrow infiltration patterns in MM patients can indicate the tumor burden and ADC value has the ability to discriminate these patterns objectively....
Resection beyond the contrast-enhanced zone contributed to reduce tumor burden and prolong survival in glioblastomas. The optimal extent of resection (EOR) and how to achieve it are worthy of continuo...
A total of 340 adult supratentorial lobar glioblastomas (included astrocytoma, WHO 4, IDH mutation and glioblastoma) were retrospectively evaluated. The clinical data, EOR, technique of resection, pos...
Supramaximal resection (SMR) was confirmed as resection with 100% EOR...
Applying en-bloc technique and achieving SMR, which could reduce tumor burden and did not increase additional complications, both had remarkedly positive effects on clinical outcomes in patients with ...